|
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 20 new drugs in its recent meeting, under the provisions of the Drugs Prices Control Order (DPCO), 2013, including hypertensive medicines, ophthalmic solutions, among others.
The Authority has also notified the retail prices, following the meeting held on February 27, 2026.
Various formulations and strengths of drugs for which prices has been fixed include Cetrizine ophthalmic solution, and combination of Rosuvastatin and Clopidogrel tablets from Sun Pharma Laboratories, Dehydroepiandrosterone (DHEA) (micronized) and folic acid hard gelatin capsule from Mankind Pharma, two strengths of combination of Metoprolol Succinate ER, cilnidipine and telmisartan tablets from Ipca Laboratories, and combination of Mecobalamin, alpha lipoic acid, vitamin D3, pyridoxine hydrochloride and folic acid tablets from Mankind Prime Labs.
Other formulations for which retail prices were notified include combination of atorvastatin and clopidogrel capsules from Macleods Pharmaceuticals, two strengths of combination of Atorvastatin, clopidogrel and aspirin capsules from Akums Drugs & Pharmaceuticals Ltd, combination of Bilastine and montelukast oral suspension from Hetero Healthcare Ltd, two strengths of combination of Bisoprolol Fumerate and telmisartan tablets from Alkem Wellness, Cetrizine ophthalmic solution from Micro Labs, a formulation of Levofloxacin eye drops and another formulation of Tacrolimus ointment from German Remedies Pharmaceuticals, combination of Cilnidipine and telmisartan tablets from SRK Puremed LLP, two strengths of combination of Empagliflozin, Sitagliptin, and Metformin hydrochloride extended release tablets from Kollectcare, among others.
Earlier, in a meeting in January 30, 2026, the drug price regulator has fixed the retail price of 37 new drugs including hypertensive medicines, anti-diabetic medicines and others from various drug majors including Sun Pharma Laboraotries Dr Reddy's Laboratories, Zydus Healthcare, Mankind Pharma, among others.
These are new drugs, under paragraph 2(1)(u) of the Drugs Prices Control Order (DPCO), 2013.
Under the Paragraph 2(1)(u) of the DPCO, 2013, a new drug is defined as a a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines (NLEM) by combining the drug with another drug either listed or not listed in the NLEM or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the NLEM.
The methodology of calculating and fixing the retail price of new drugs for existing manufacturers of scheduled formulations are specified in the Para 5 and 15 of the DPCO, 2013, which is followed by the NPPA to arrive at the price against the applications submitted by the companies.
In case the retail price of any of these formulations are not complied with, as per the price notifications and notes released by the authority, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, added the price regulator.
|